Skip to main content
Journal ArticleOPEN ACCESS

CD-20 expression in post-transplant lymphoproliferative disorders: Treatment with rituximab

American Journal of Hematology (2000) 65(2) 171-173
DOI: 10.1002/1096-8652(200010)65:2<171::AID-AJH14>3.0.CO;2-Z
34Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

B-cell lymphoproliferative disorders are rare but serious complications of solid organ and bone marrow transplantation. We report that these tumors frequently express the CD-20 antigen, and immunotherapy directed at this antigen may be a well-tolerated and effective treatment. (C) 2000 Wiley-Liss, Inc.

Author supplied keywords

Cite

CITATION STYLE

APA

Ifthikharuddin, J. J., Mieles, L. A., Rosenblatt, J. D., Ryan, C. K., & Sahasrabudhe, D. M. (2000). CD-20 expression in post-transplant lymphoproliferative disorders: Treatment with rituximab. American Journal of Hematology, 65(2), 171–173. https://doi.org/10.1002/1096-8652(200010)65:2<171::AID-AJH14>3.0.CO;2-Z

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free